ReCode finishes enrolling its inhaled mRNA trial in cystic fibrosis

ReCode Therapeutics said on 6 August 2026 that the Phase 2a study of RCT2100 is fully enrolled and still running, with data expected in the fourth quarter of 2026. RCT2100 is an inhaled mRNA therapy for cystic fibrosis: rather than correcting the defective CFTR gene, it delivers instructions for the chloride channel the gene fails to produce, breathed directly into the lung.

That distinction is what makes the readout worth waiting for. The modulator drugs that transformed cystic fibrosis care work by rescuing a faulty protein, which requires there to be a protein to rescue. Patients whose mutations produce none have largely been left out of that decade of progress. An mRNA therapy is aimed at exactly that gap — and, being transient, it has to be re-administered rather than given once.

The same release announced new funding from the Cystic Fibrosis Foundation supporting a collaboration with an unnamed gene-editing company on CFTR genetic medicines, and a leadership change: Heather Clark became chief executive on 1 July 2026, with Shehnaaz Suliman moving to executive chair. The foundation did not disclose the amount.